(BD: Binding Domain)

The Candidate


We designed our EGFR-TRACTr product candidate as a double-masked TRACTr in which the EGFR-binding domain and the T cell-specific binding domain (CD3e) is masked.

Improving upon prior approaches
Our EGFR-TRACTr is designed to target EGFR, a well-validated target that is over expressed in many cancer types. For example, Colorectal cancer represents one tumor type for which EGFR is overexpressed, but over 85 percent of patients do not respond to anti-EGFR mAbs and, of those that do, resistance often develops. We believe that EGFR-directed immunotherapies, including TCEs, have the potential to address this high unmet need.

Preclinical Data


Our EGFR-TRACTr had a half-life of approximately 94 hours in NHPs, which we believe is in line with once-weekly dosing in humans 


Dosing of our EGFR-TRACTr in NHPs had minimal effects on inflammatory cytokine levels. In contrast, dosing of an EGFR-TCE led to substantial levels of IL-6 as well as elevation of other inflammatory cytokines commonly observed in CRS